Long-term follow-up for 39 newly diagnosed diffused large B-cell lymphoma patients treated by (R)-EPOCH.
10.7534/j.issn.1009-2137.2014.02.013
- Author:
Xiao-Yan YANG
1
;
Yong-Ping ZHAI
2
;
Hai-Ning LIU
1
;
Ya-Ping YU
1
;
Feng LI
1
;
Ping SONG
3
;
Xiao-Gang ZHOU
1
;
Zhi-Ming AN
1
;
Li-Ping WANG
1
Author Information
1. Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China.
2. Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province, China. E-mail: ypzhai@medmail.com.cn.
3. Department of Hematology,Nanjing School of Clinical Medicine,Southern Medical University/Nanjing General Hospital of Nanjing Military Command,Chinese PLA,Nanjing 210002,Jiangsu Province,China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cyclophosphamide;
therapeutic use;
Doxorubicin;
therapeutic use;
Etoposide;
therapeutic use;
Female;
Follow-Up Studies;
Humans;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
Male;
Middle Aged;
Prednisone;
therapeutic use;
Vincristine;
therapeutic use;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(2):333-338
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to evaluate the efficacy and safety of (R)-EPOCH protocol on patients with diffuse large B-cell lymphoma(DLBCL). From February 2004 to April 2009, a total of 39 patients who suffered from DLBCL and received (R)-EPOCH protocol were enrolled in the study. The median age of patients was 52 years old. 24 patients were on stage I/II, and 15 cases were on stage III/IV. Patients with stage I/II were administered with 4-6 cycles of (R)-EPOCH, while other patients with stage III/IV received 6-8 cycles of (R)-EPOCH. DLBCL patients with bulky disease received radiotherapy after completion of chemotherapy. 39 patients received a total of 209 cycles of chemotherapy and the median chemotherapy cycles was 6 (range, 2-8 cycles). The results showed that the overall response rate of 39 assessable patients was 87.2%, including 28 patients (71.8%) in complete remission (CR) and 6 patients (15.4%) in partial remission(PR). With a median follow-up of 57.7 months, the 1-year overall survival rate was 81.8%, while 70.9% for 3-year and 58.8% for 5-year. The major toxicity of (R)-EPOCH protocol was hematologic toxicity and the incidence of grade III-IV neutropenia and anemia were 29.2% and 14.4%, respectively. Other toxicities were mild, no treatment-related deaths occurred. At the end of follow-up,no secondary tumors occurred. It is concluded that (R)-EPOCH protocol is a effective and safe protocol for the patients with DLBCL.
